X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.
Lead Product(s): ALRN-6924
Therapeutic Area: Dermatology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities.
Lead Product(s): ALRN-6924
Therapeutic Area: Dermatology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancer.
Lead Product(s): ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
ALRN-6924, first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy.
Lead Product(s): ALRN-6924,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities.
Lead Product(s): ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Non-clinical data demonstrated principle that ALRN-6924 can temporarily arrest cell cycle in human scalp hair follicles and their stem cells also ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damage.
Lead Product(s): ALRN-6924,Paclitaxel
Therapeutic Area: Dermatology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
ALRN-6924 is first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21
Lead Product(s): ALRN-6924
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
A precision medicine-based chemoprotective agent, ALRN-6924 is designed to selectively activate p53 in normal cells, thereby upregulating p21, which pauses cell cycle in normal cells but not in p53-mutated cancer cells.
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal bone marrow cells in healthy volunteers.
Lead Product(s): ALRN-6924,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2021
Details:
Aileron is developing ALRN-6924 as a novel medicine to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy’s effects against cancer cells.
Lead Product(s): ALRN-6924,Carboplatin
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Acorn Bioventures
Deal Size: $35.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2021
Details:
The data to be presented is from Aileron’s Phase 1b study, evaluating ALRN-6924 as a therapeutic agent administered ahead of chemotherapy to prevent chemotherapy-induced toxicities in patients with p53-mutated small cell lung cancer who are being treated with topotecan.
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Aileron intends to use the net proceeds from the transaction for general corporate purposes and extending its cash runway to support its ALRN-6924 clinical development strategy.
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital Fund
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Agreement September 21, 2020
Details:
Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan .
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Observed a protective effect against severe chemotherapy-induced anemia and thrombocytopenia across all dose levels. Patients treated with 0.3 mg/kg ALRN-6924 met the protocol-defined criteria for reduction of NCI CTC Grade 3/4 neutropenia to ≤50% in the first treatment cycle.
Lead Product(s): ALRN-6924
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
The Phase 1b study is designed to identify a dose and a schedule of ALRN-6924 administration to reduce chemotherapy toxicities such as severe anemia and thrombocytopenia, and other toxicities resulting from topotecan.
Lead Product(s): ALRN-6924
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
